Edward James Martin

US Patent:

20090234225, Sep 17, 2009

Filed:

Jan 12, 2009

Appl. No.:

12/352408

Inventors:

Edward W. Martin - Delaware OH, US
Ronald X. Xu - Columbus OH, US
Duxin Sun - Ann Arbor MI, US
Stephen P. Povoski - Dublin OH, US
Joseph Pierre Heremans - Upper Arlington OH, US
Robert Lee - Hilliard OH, US
Vish V. Subramaniam - Westerville OH, US
Claudia Turro - Powell OH, US

Assignee:

The Ohio State University Research Foundation - Columbus OH

International Classification:

A61B 6/00
A61K 49/00

US Classification:

600431, 424 96

Abstract:

Exemplary embodiments include systems, methods, and compositions for the intra-operative detection of target tissue. At least one embodiment includes a fluorescence detection instrument that may be used for intra-operative detection of a fluorescent targeting agent, its binding site, and its interaction within cancer tissues. An exemplary embodiment is highly sensitive to the local deposition of fluorescence agents even at a low concentration. In at least one embodiment, the system includes a handheld navigation instrument that is usable to excite, detect, and report the fluorescent deposition of the targeting agent in real-time. In alternative embodiments, the system includes a wearable unit to excite, detect, and visually report the fluorescent deposition of the targeting agent to the user. The wearable unit includes eyewear that allow the user to perform image-guided surgery based on the near real-time fluorescence detection of the fluorescent targeting agent.

US Patent:

47828404, Nov 8, 1988

Filed:

Sep 10, 1986

Appl. No.:

6/905880

Inventors:

Edward W. Martin - Delaware OH
Marlin O. Thurston - Columbus OH

Assignee:

Neoprobe Corporation - Columbus OH

International Classification:

A61B 1000

US Classification:

128654

Abstract:

The present invention is addressed to a method for the improved localization, differentiation, and removal of neoplastic tissue in animals. In particular, one aspect of the present invention involves a surgical procedure wherein an animal suspected of containing neoplastic tissue is surgically accessed and the tissue therein examined visually and by palpation for evidence of neoplastic tissue. The improved methodology commences with the administering to the animal of an effective amount of a labelled antibody specific for neoplastic tissue and labelled with a radioactive isotope exhibiting specific photon emissions of energy levels. Next, and importantly, the surgial procedure is delayed for a time interval following said administering for permitting the labelled antibody to preferentially concentrate in any neoplastic tissue present in the animal so as to increase the ratio of photon emissions from neoplastic tissue to background photon emissions in said animal. Thereafter, an operative field of the animal is surgically accessed and tissue within the operative field to be examined for neoplastic tissue has the background photon emission count determined. Once the background photon emission account for tissue within the operative field has been determined, a handheld probe is manually positioned within the operative field adjacent tissue suspected of being neoplastic.

US Patent:

55906567, Jan 7, 1997

Filed:

Aug 31, 1993

Appl. No.:

8/114675

Inventors:

Thomas M. O'Dorisio - Worthington OH
M. Sue O'Dorisio - Worthington OH
Edward W. Martin - Delaware OH
Eugene A. Woltering - Kenner LA

Assignee:

The Ohio State University Research Foundation - Columbus OH

International Classification:

A61B 600

US Classification:

128654

Abstract:

Broadly, the present invention is directed to a method for the detection and differentiation of neoplastic tissue in a patient suspected of having neoplastic tissue. The method includes the administration of a radiolabeled somatostatin congener to the patient and accessing the patient with a radiation detection probe for determining tissue exhibiting elevated levels of radiation, viz. , neoplastic tissue. However, before subjecting the patient to such administration, an initial determination preferably is made as to whether the radiolabeled somatostatin congener will bind to the tumor site, i. e. , whether somatostatin receptors are associated with the neoplastic tissue. This is conveniently done with a wide variety of endocrine tumors, which release peptides or hormones, referred to as "biochemical markers. " In order to make this determination, initially a biochemical marker-inhibiting dose of unlabeled somatostatin congener is administered to the patient. The biochemical marker associated with the neoplastic tissue then is monitored to determine whether the administered somatostatin congener reduces the presence of the marker in the patient.

US Patent:

58142959, Sep 29, 1998

Filed:

Jul 13, 1994

Appl. No.:

8/271902

Inventors:

Edward W. Martin - Delaware OH
Brian J. Czerniecki - Gaithersburg MD
Pierre L. Triozzi - Columbus OH
Julian A. Kim - Columbus OH

Assignee:

The Ohio State University Research Foundation - Columbus OH

International Classification:

A61K 5100
G01N 100

US Classification:

424 149

Abstract:

The present invention is directed to a method for reliably determining lymph nodes enriched in tumor reactive cells, e. g. , CD4+tumor-specific lymphocytes. This method includes the steps of administering to a patient an effective amount of a radiolabeled locator which specifically binds a marker produced by or associated with neoplastic tissue. Time is permitted to elapse following the administration for the radiolabeled locator to preferentially concentrate in any neoplastic tissue and for unbound radiolabeled locator to be cleared, so as to increase the ratio of photon emissions from neoplastic tissue to background photon emissions in the patient. After the time has elapsed, the patient is accessed with a radiation detection probe for determining lymph node sites exhibiting accretion of the radiolabeled locator by detecting with the probe elevated levels of radiation at the lymph node sites. The lymph node sites exhibiting such elevated levels of radiation are removed and subjected to gross visual analysis, though such sites alternatively may be subjected to histological analysis. Those determined and removed lymph nodes that also are determined to be tumor-free by gross observation or free of gross metastatic disease are selected and cultured to proliferate tumor reactive cells.

US Patent:

54820405, Jan 9, 1996

Filed:

Apr 14, 1994

Appl. No.:

8/227447

Inventors:

Edward W. Martin - Delaware OH

Assignee:

The Ohio State University Research Foundation - Columbus OH

International Classification:

A61B 600

US Classification:

1286531

Abstract:

Broadly, the present invention is directed to a method for reliably staging adenocarcinomas typified by colorectal cancer in patients who are undergoing surgery therefor. The method includes the administration of a radiolabeled tumor-associated glycoprotein (TAG) antibody (or other equivalent locator) to the cancer patient prior to surgical accession of the patient. Desirably, the present method includes surgical accession with a radiation detection probe for determining tissue exhibiting elevated levels of radiation. The preferred radiolabel is. sup. 125 I, which is used to label an antibody specific to a high molecular weight glycoprotein called TAG-72. The preferred antibody is CC49, a murine monoclonal antibody of the IgG. sub. 1 subclass. With radiolabeled monoclonal antibody CC49, it preferably is administered to the patient approximately 21 days (. +-.

US Patent:

20190321065, Oct 24, 2019

Filed:

Jul 2, 2019

Appl. No.:

16/459995

Inventors:

- Columbus OH, US
Edward W. Martin - Delaware OH, US
Stephen P. Povoski - Dublin OH, US
Charles L. Hitchcock - Upper Arlington OH, US
Enver Ozer - Columbus OH, US
Ronald Xu - Columbus OH, US

International Classification:

A61B 17/3211
A61B 5/06
B25J 9/16
A61B 34/30
A61B 34/00
A61B 6/00
A61B 6/12
A61B 34/20

Abstract:

Systems and methods are described for performing navigation-assisted medical procedures such as biopsies, surgeries and pathology procedures by obtaining location information of an item of interest located within at least a portion of a subject; sensing position information of a moveable device; determining a relative position of the moveable device to the item of interest using the location information of the item of interest and the position information of the moveable device; and providing feedback based on the relative position of the moveable device to the item of interest that can be used to change the relative position of the moveable device to the item of interest.

US Patent:

20190110687, Apr 18, 2019

Filed:

Mar 16, 2017

Appl. No.:

16/085210

Inventors:

- Columbus OH, US
Heather ALLEN - Columbus OH, US
Charles HITCHCOCK - Upper Arlington OH, US
Edward W. MARTIN - Delaware OH, US

Assignee:

Ohio State Innovation Foundation - Columbus OH

International Classification:

A61B 5/00
G01J 3/42

Abstract:

Disclosed are systems and methods utilizing an infrared probe and discriminating software to rapidly discriminate normal tissue processes from normal tissue during surgery, physical examination of in-situ lesions, and in the assessment of biopsy and resected tissue specimens. Examples demonstrate discrimination of cancerous from noncancerous tissues. The discriminating software, i.e. the metrics, algorithms, calibrant spectra, and decision equations, allows tissue to be identified as abnormal or normal using a minimum of infrared (IR) wavelengths in order to be measured rapidly. The probe records IR metrics approximately 1000 times faster than current commercial instruments, i.e. on a timescale fast enough for clinical use. The probe uses a tunable mid-infrared laser with a small set of selected wavelengths that are optimized for detecting the chemical and molecular signatures of tissue specific lesions to include, but not limited to, cancer, preneoplasia, intracellular accumulations (e.g. steatosis), inflammation, and wound healing.

US Patent:

20180037663, Feb 8, 2018

Filed:

Jul 31, 2017

Appl. No.:

15/664425

Inventors:

- Columbus OH, US
Brandon J. Sullivan - Gahanna OH, US
Heather C. Allen - Columbus OH, US
Edward W. Martin - Delaware OH, US
Charles L. Hitchcock - Arlington OH, US
E. David Alten - Loveland OH, US
Nicholas E. Long - Columbus OH, US

International Classification:

C07K 16/30
A61K 45/06
A61K 51/10
C12N 5/09
A61K 39/395
A61N 5/10
C12N 15/86
C12N 5/10
C12N 15/62
C12N 15/66

Abstract:

Disclosed herein are methods and compositions related to single chain antibody fragments which specifically bind sialyl-Tn epitope of tumor-associated glycoprotein 72 (TAG-72).